cough variant asthma
Conditions
Interventions
Ozagrel
histamine H1 receptor antagonist
Sponsors
Graduate School of Medical Sciences, Nagoya City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cough variant asthma patients 16 years or older who are taking inhaled corticosteroid, long-acting bronchocilator, leukotriene receptor antagonist treatments.
Exclusion criteria
Exclusion criteria: 1. Patients with suspicion of infectious disease such as pulmonary tuberculosis. 2. Current smoker, ex-smoker with smoking history within 6 months, ex-smoker with smoking history more than 5 pack-years. 3. Gastroesophageal reflux disease patients with scores of Frequency Scale for the Symptoms of GERD (FSSG) more than eight. 4. Patients with tendency to hemorrhages. 5. Patients who takes histamine H1 receptor antagonist, anti-thromboxane agent, angiotensin converting enzyme inhibitor, or Non-Steroidal Anti-Inhlammatory Drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response of cough symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Improvement of capsaicin cough sensitivity. 2) Changes of Thromboxane B2 (TXB2)concentration in sputum. Correlation between changes of TXB2 concentration and a) Changes of scores in Leister cough questionnaire b) Improvement of capsaicin cough sensitivity c) Falling rate of sputum eosinophil count d) Reduction rate of fractional exhaled nitric oxide and improvement of spirometry , Impulse Oscillation System. e) Changes of MUC5AC concentration. | — |
Countries
Japan
Contacts
Public ContactTakamitsu Asano
Graduate School of Medical Sciences, Nagoya City University Respiratory Medicine, Allergy and Clinical Immunology
Outcome results
None listed